Spinal Intramedullary Solitary Fibrous Tumor: A Rare and Challenging Diagnosis

Chenlong Yang\1
Yulun Xu\2
Xiaoguang Liu\1

1Department of Orthopedics, Peking University Third Hospital, Beijing 100191, People’s Republic of China; 2Department of Neurosurgery, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, People’s Republic of China

Background: Solitary fibrous tumor (SFT) is a benign neoplasm arising in the soft tissue, which can occur anywhere in the body, while it is predominantly found in the visceral pleura. Spinal SFT is quite uncommon, with limited cases having been reported in the literature; especially, SFT occurring in the intramedullary site is extremely rare.

Case presentation: We present a case of a 35-year-old woman presenting with progressive numbness and weakness in the legs and urinary incontinence. Magnetic resonance imaging (MRI) showed an intramedullary lesion with bright enhancement. A diagnosis of spinal hemangioblastoma was suspected, and thus a three-dimensional computed tomographic angiography reconstruction was requested, which also demonstrated an angiomatous lesion. The tumor was completely resected under neurophysiological monitoring. However, histopathological and immunohistochemical examinations revealed an SFT. No adjuvant radiotherapy or chemotherapy was scheduled. The symptoms were relieved completely, and no recurrence or progression was noted during the follow-up.

Conclusion: Though SFT has been considered similar to malignant hemangiopericytoma and the histological classification has always been controversial, the intramedullary location and benign behavior in the present case add to the current understandings of this extremely rare entity.

Keywords: solitary fibrous tumor, spinal tumor, intramedullary tumor, MRI, CTA, case report

Background
Solitary fibrous tumor (SFT) is a benign mesenchymal neoplasm of putative fibroblastic origin. They can occur anywhere in the human body but arise predominantly in the visceral pleura; SFTs in extraserosal sites, especially those involving the central nervous system, are quite infrequent.1-3 SFTs occurring in the spinal intramedullary locations are extremely rare.4-8 Although it may be challenging on neuroimages to offer a specific diagnosis of this rare entity, knowledge of this tumor is vital as it has benign features and a possibly better prognosis than some more malignant tumors in this location.4,7 It is crucial to accumulate imaging findings and biological behaviors of spinal intramedullary SFTs given the limited number of reported cases.

Herein, we described a rare spinal intramedullary SFT. On neuroimaging, the tumor appeared as an angiomatous lesion; the preoperative diagnosis is challenging. The clinical manifestations, radiological features, histopathological findings, and follow-up data were presented and discussed.

Correspondence: Xiaoguang Liu; Yulun Xu
Email liuxg.puth@hotmail.com; xuhuxi@sina.cn
Case Presentation

History

A 35-year-old female presented with an 11-month history of progressive numbness in both of her legs. Over the last month, she developed weakness in her left leg and loss of bladder control. Physical examination showed a loss of sensation below the level of crista iliaca and muscle strength of grade 4/5 in the left lower extremity. There was no remarkable finding in her past medical history, and she denied a family history of central nervous system diseases.

Examinations

The laboratory data were all in the normal range. Magnetic resonance imaging (MRI) showed an intramedullary well-circumscribed 4.3×0.9×1.3 cm mass at the C6-T1 vertebral level and associated spinal cord edema in the rostral region of the lesion. The lesion was isointense on T1-weighted imaging (Figure 1A) and hyperintense on T2-weighted imaging (Figure 1B). Homogeneous and bright contrast enhancement was noted after intravenous injection of gadolinium-diethylenetriamine penta-acetate (Gd-DTPA) (Figure 1C). A further three-dimensional computed tomographic angiography (CTA) reconstruction was requested, which demonstrated the mass was remarkably enhanced (Figure 1D), suggesting its rich vascularization; nevertheless, identifying its definite feeding artery is quite challenging.

Operation

The preoperative suspected diagnosis was spinal hemangioblastoma. The tumor was surgically resected via a posterior midline approach, under neurophysiological monitoring with motor and sensory evoked potentials. Intraoperative findings revealed an intramedullary white-yellowish tumor. There was no cleavage plane between the tumor and the parenchyma of the spinal cord. A gross total resection was achieved.

Pathological Findings

Histological examination revealed uniform spindle cells arranged in interlacing fascicles, with intermingled collagen fiber bundles and a dense reticulin fiber network. The nuclei were oval to elongated without pleomorphism. Mitotic activity and necrosis were absent. There were no psammoma bodies or whorls. Immunohistochemical analysis revealed strong and diffuse immunopositivity with vimentin and CD34, while the tumor was negative for S-100, glial fibrillary acidic protein (GFAP), epithelial membrane antigen (EMA), and CD56. The Ki-67 labeling index was low (<1%). Based on the immunohistochemical profiles and the histopathological fascicular spindle cell morphology, the lesion was diagnosed as SFT (Figure 2A).

Postoperative Course and Follow Up

The postoperative MRI confirmed a complete resection (Figure 2B–D), and the postoperative course was uneventful. The paresthesia and weakness in the lower extremities and dysuria were completely relieved seven months postoperatively. The patient was asymptomatic over the subsequent 23-month follow-up. The latest MRI showed no evidence of recurrence.

Discussion

SFTs were initially described in 1931 by Klemperer and Rabin as a mesenchymal tumor arising from the pleura.

---

Figure 1 (A) T1-weighted magnetic resonance imaging showing an isointense mass. (B) T2-weighted imaging showing a hyperintense mass with associated spinal cord edema in the rostral region of the lesion. (C) Homogeneous enhancement after gadolinium administration. (D) Three-dimensional computed tomographic angiography reconstruction showing a high-flow hypervascular lesion.
The visceral pleura is the predominant location, while the central nervous system involvement is quite infrequent; SFTs occurring within the spinal cord is extremely rare, with only 18 cases previously reported in the literature. The relevant literature review was summarized in Table 1. We analyzed the clinical and radiological characteristics of intramedullary SFTs in 18 reported cases together with the current case. The average age at diagnosis was 48.95 ± 17.08 years (range, 17–83 years). The female-to-male ratio was 1.25:1. The clinical manifestations were nonspecific, including local pain and sensorimotor disturbances. The duration between onset and diagnosis ranged from 1 month to 3 years (mean 15.72 ± 11.35 months). These tumors were predominantly located in the cervical (n=8) and thoracic (n=9) spine, and only one intramedullary SFT in the lumbar spine was reported. Approximately half of these tumors (n=9) were exophytic to the extramedullary compartment. Fifteen patients underwent completely surgical resection, among which tumor recurrent was noted only in one patient during the follow-up; four patients underwent incompletely surgical resection, and one of them experienced tumor recurrence.

SFTs must be differentiated from hemangioblastoma, hemangiopericytoma, and fibrous meningioma; nevertheless, the preoperative identification is difficult as they can show similar appearance in imaging studies. The confident diagnosis still relies on histopathology. The typical microscopic characteristics of SFTs are fasicular spindle cells, dense collagenous band, and absence of specific structural features such as well-formed lobules, whorls, or psammoma bodies. Immunoreactivity of SFTs to CD34 and negative to S-100 and EMA distinguish them from the other spindle cell tumors. Additionally, hemangiopericytomas can also be positive for CD34 antigen; nevertheless, these tumors are typically hypercellular with a higher mitotic rate and presence of necrosis; hemangiopericytomas exhibit patchy and focal expression of CD34, whereas SFTs show strong and diffuse reactivity.

The natural history and biological behavior of SFTs are as yet unclear, and there appears to be a variation in tumor growth rates and recurrence; however, it usually has an indolent course as reflected in the WHO classification of the tumors of the central nervous system. According to the 2007 classification criteria, SFT was classified as an independent benign pathological variation corresponding to grade I. However, SFTs show many similarities to more malignant hemangiopericytomas histopathologically; over the past decade, many scholars assume a common spectrum of these tumors, whereas neuropathologists have retained the distinction of these two entities given the historical understanding and distinct clinicopathologic correlations. Hemangiopericytoma is generally considered with high recurrence rates and long-term risk of systemic metastasis. In the updated WHO classification of CNS tumors (2016 version), these two pathological items were replaced by a new combined term “solitary fibrous tumor/hemangiopericytoma”, and a grading system was adopted to identify the low-grade SFT and the higher-grade lesions including hemangiopericytoma and anaplastic hemangiopericytoma. Herein, we highlight the importance of making the correct diagnosis in terms of management and prognosis.

SFTs are indolent neoplasms that can be cured by complete surgical resection. As to spinal intramedullary lesions, a surgical strategy including laminotomy and gross total tumorectomy is the optimal option. Surgical resection should
Table 1: Previously Reported Cases of Intramedullary Solitary Fibrous Tumor

<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Age (Years) / Gender</th>
<th>Symptoms</th>
<th>Duration</th>
<th>Location</th>
<th>Exophytic to Extramedullary Compartment</th>
<th>Resection</th>
<th>Follow-Up</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>Carneiro et al</td>
<td>50/F</td>
<td>Bilateral lower-extremity pain, numbness and weakness; incontinence</td>
<td>3 years</td>
<td>N.A.</td>
<td>Yes</td>
<td>Incomplete</td>
<td>5 years</td>
<td>Recurrence</td>
</tr>
<tr>
<td>1997</td>
<td>Alston et al</td>
<td>47/M</td>
<td>Brown-Sequard syndrome</td>
<td>1 year</td>
<td>T4-5</td>
<td>No</td>
<td>Complete</td>
<td>2 months</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2000</td>
<td>Mordani et al</td>
<td>33/M</td>
<td>Four-extremity paresthesia; bilateral lower-extremity weakness</td>
<td>18 months</td>
<td>C5</td>
<td>No</td>
<td>Complete</td>
<td>18 months</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2004</td>
<td>Kawamura et al</td>
<td>64/M</td>
<td>Brown-Sequard syndrome</td>
<td>2 years</td>
<td>T2-3</td>
<td>Yes</td>
<td>Incomplete</td>
<td>6 months</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2004</td>
<td>Bohinski et al</td>
<td>49/F</td>
<td>Neck pain and stiffness; burning sensation in the left upper extremity</td>
<td>1 year</td>
<td>C4</td>
<td>Yes</td>
<td>Complete</td>
<td>10 months</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2004</td>
<td>Pizzolitto et al</td>
<td>47/M</td>
<td>Anesthesia; four-extremity paresthesia</td>
<td>6 months</td>
<td>C4</td>
<td>N.A.</td>
<td>Complete</td>
<td>12 months</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2005</td>
<td>Jallo et al</td>
<td>41/M</td>
<td>Anesthesia; upper-extremity weakness</td>
<td>24 months</td>
<td>C6-7</td>
<td>No</td>
<td>Complete</td>
<td>3.5 years</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2005</td>
<td>Jallo et al</td>
<td>17/M</td>
<td>Back pain; lower-extremity weakness; scoliosis</td>
<td>6 months</td>
<td>T5-6</td>
<td>No</td>
<td>Complete</td>
<td>1.6 years</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2009</td>
<td>Ishii et al</td>
<td>63/F</td>
<td>Neck pain; right upper-extremity numbness, paresthesia, and weakness</td>
<td>6 months</td>
<td>C5</td>
<td>No</td>
<td>Complete</td>
<td>14 months</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2010</td>
<td>Ciappetta et al</td>
<td>75/F</td>
<td>Bilateral lower-extremity weakness and paresthesia</td>
<td>1 year</td>
<td>T6-7</td>
<td>Yes</td>
<td>Complete</td>
<td>2 years</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2011</td>
<td>Fargen et al</td>
<td>28/F</td>
<td>Face, neck and shoulder pain; lower-extremity numbness</td>
<td>N.A.</td>
<td>C2-3</td>
<td>Yes</td>
<td>Complete</td>
<td>2 years</td>
<td>Nodular enhancement</td>
</tr>
<tr>
<td>2012</td>
<td>Mariniello et al</td>
<td>75/F</td>
<td>Bilateral lower-extremity weakness and paresthesia</td>
<td>1 year</td>
<td>T6-7</td>
<td>N.A.</td>
<td>Complete</td>
<td>1 year</td>
<td>No recurrence</td>
</tr>
<tr>
<td>2014</td>
<td>Robert et al</td>
<td>49/F</td>
<td>Bilateral lower-extremity numbness and paresthesia</td>
<td>1 year</td>
<td>T9-10</td>
<td>Yes</td>
<td>Incomplete</td>
<td>6 months</td>
<td>No recurrence</td>
</tr>
</tbody>
</table>
be performed carefully under neurophysiological monitoring as these tumors are usually well-circumscribed but can present with a firm spinal cord attachment. Considering the benign nature of SFTs, no adjuvant radiotherapy or chemotherapy is needed in these cases. Recurrence is extremely rare after gross total removal but has been reported after subtotal resection.\(^4\) Chemotherapy has been administered in some recurrent cases, while the therapeutic efficacy remains indefinite.\(^23\) SFTs seem to be insensitive to radiotherapy and chemotherapy.\(^23\) Though SFTs with malignant transformation has been rarely reported in the literature, expression of Ki-67 can help determine the possibility of malignant transformation; malignant transformation of SFT has only been reported in cases with high expression of Ki-67 (up to 10%).\(^22\)

### Conclusions

The rarity and the differential diagnosis of this diagnostically challenging tumor should be highlighted. It is crucial for the clinicians to be aware of intraspinal SFT as it can be easily mistaken for more common angiomatous tumors occurring at this site.

### Consent for Publication

Institutional Review Board approval was granted to publish this case. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

### Acknowledgements

The authors would like to thank the patient and her family who trusted us with the care, and all of the physicians and staff who helped in this study.

### Disclosure

The authors have no financial interests or potential conflicts of interest to report in this work.

### References


### Table

<table>
<thead>
<tr>
<th>Year</th>
<th>Case Information</th>
<th>Initial Symptoms</th>
<th>Follow-up</th>
<th>Recurrence</th>
<th>N.A.</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>Hwang et al.(^7)</td>
<td>48M</td>
<td>Right lower-extremity paresthesia and hypoesthesia</td>
<td>1 month</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>2014</td>
<td>Bruder et al.(^4)</td>
<td>8F</td>
<td>Left lower-extremity weakness and paresthesia; paraparesis; incontinence</td>
<td>1.5 years</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>2015</td>
<td>Walker et al.(^9)</td>
<td>47F</td>
<td>Right lower-extremity paresthesia and hypoesthesia</td>
<td>3 years</td>
<td>N.A.</td>
<td>C7-T1</td>
</tr>
<tr>
<td>2015</td>
<td>Walker et al.(^10)</td>
<td>31M</td>
<td>Bilateral lower-extremity weakness and paresthesia</td>
<td>1 year</td>
<td>N.A.</td>
<td>C7-T1</td>
</tr>
<tr>
<td>2016</td>
<td>Wang et al.(^11)</td>
<td>48N.A.</td>
<td>Bilateral lower-extremity weakness and paresthesia</td>
<td>1 year</td>
<td>No</td>
<td>N.A.</td>
</tr>
<tr>
<td>2019</td>
<td>Mansilla et al.(^12)</td>
<td>35F</td>
<td>Right lower-extremity paresthesia and hypoesthesia</td>
<td>11 months</td>
<td>No</td>
<td>N.A.</td>
</tr>
<tr>
<td>2019</td>
<td>Yang et al.(^13)</td>
<td>Present case</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: N.A., not available.
Yang et al

Cancer Management and Research 2019:11

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Cancer Management and Research downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Jan-2020
For personal use only.
Powered by TCPDF (www.tcpdf.org)